Samuel Blackman

Stories

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

Retired from Day One in late 2024; joined Pediatric Brain Tumor Foundation board

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.

Updated May 30